For its lead compound, Antithrombin III, the Company has completed one of two identical Phase III clinical studies for the treatment of heparin resistance in-patients undergoing cardiopulmonary bypass procedures.
Revenues reflect a higher number of transgenic programs.
Lower loss reflects an increase in interest income. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Event data provided by StreetEvents .